Nurix therapeutics’ chief scientific officer sells $38,841 in stock

Gwenn Hansen, the Chief Scientific Officer of Nurix Therapeutics, Inc. (NASDAQ:NRIX), recently sold shares of the company’s common stock valued at approximately $38,841. The transaction comes as the company, currently valued at $885 million, trades near $11.50 per share, down over 53% in the past six months. According to InvestingPro analysis, the stock appears undervalued based on its Fair Value assessment. The transaction, which took place on April 30, 2025, involved the sale of 3,377 shares at an average price of $11.50 per share. This sale was conducted to cover tax withholding obligations associated with the vesting of restricted stock units (RSUs), as mandated by the company’s equity incentive plans. InvestingPro data reveals the company maintains a strong financial position with a current ratio of 6.26, indicating robust liquidity.

In addition to the sale, Hansen executed multiple transactions involving restricted stock units. These transactions added a total of 8,956 shares to her holdings, with no purchase price involved as the RSUs were converted into common stock. Following these transactions, Hansen’s direct ownership in Nurix Therapeutics stands at 61,516 shares.

The sale was part of a pre-arranged plan to manage tax obligations, and not a discretionary trade by Hansen. The weighted average sale price ranged between $11.05 and $11.72 per share.

In other recent news, Nurix Therapeutics has reported promising preclinical data on several drug candidates at the American Association for Cancer Research 2025 Annual Meeting. The company’s brain-penetrant small molecule degrader, bexobrutideg, is undergoing a Phase 1a/b clinical trial for relapsed or refractory B cell malignancies, demonstrating potential efficacy at lower doses. Additionally, Nurix’s BRAF degrader, NRX-0305, has shown effectiveness across various BRAF-mutant cancers, including melanoma and non-small cell lung cancer, positioning it as a significant advancement for patients with limited options. In another development, Nurix has received FDA approval to initiate Phase 1 trials for its IRAK4 degrader, GS-6791/NX-0479, in collaboration with Gilead Sciences (NASDAQ:GILD), with a $5 million payment marking a milestone in their partnership.

Analysts have also weighed in on Nurix’s recent activities. UBS has adjusted its price target for Nurix to $30, down from $35, while maintaining a Buy rating, following the company’s first-quarter financial results. Stifel has similarly reduced its target to $35 from $36, maintaining a Buy rating, and highlighted the potential of Nurix’s lead asset, bexobrutideg, in the chronic lymphocytic leukemia market. Stephens has also revised its price target to $30 from $31, reaffirming an Overweight rating. These adjustments reflect increased operating expenses expected from pivotal trials and other corporate updates. Despite the reductions, the analysts remain optimistic about Nurix’s strategic developments and the potential for its stock to rise in the future.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.